Chembio Diagnostics reported positive trial results for a point-of-care syphilis test that runs on its Dual Path Platform. The trial, which involved 3,134 samples, found the test was able to detect syphilis antibodies with sensitivities and specificities of 96.7% and 99.3% respectively in whole blood, 96.4% and 99.1% in finger prick blood, 94.6% and 99.6% in blood plasma.

Related Summaries